Abivax SA (ABVX)
87.01
-1.21
(-1.37%)
USD |
NASDAQ |
Oct 07, 16:00
87.95
+0.94
(+1.08%)
After-Hours: 20:00
Abivax Total Assets (Quarterly) : 528.44M for June 30, 2026
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 528.44M |
| March 31, 2026 | 630.42M |
| December 31, 2025 | 686.28M |
| Date | Value |
|---|---|
| September 30, 2025 | 766.16M |
| June 30, 2025 | 140.44M |
| March 31, 2025 | 180.33M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Poxel SA | -- |
| OSE Immunotherapeutics SA | -- |
| Cogent Biosciences, Inc. | 834.55M |
| Arrowhead Pharmaceuticals, Inc. | 2.112B |
| Oncolytics Biotech, Inc. | 7.671M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 109.69M |
| Shareholders Equity (Quarterly) | 418.75M |
| Debt to Equity Ratio | 0.0033 |
| Current Ratio | 5.965 |
| Net Debt Paydown Yield | 0.19% |